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Abstract: Rational prescribing tools can be used by individual prescribers, organisations, and 
researchers to evaluate the quality of prescribing for research and quality improvement purposes. 
A literature search showed that there is only one tool for evaluating rational prescribing for 
paediatric patients in hospital and outpatient settings. The Pediatrics: Omission of Prescriptions 
and Inappropriate Prescriptions (POPI) tool was developed in France and comprises 105 criteria. 
The aim of this study was to modify this tool to facilitate its use in paediatric practice in the United 
Kingdom (UK). POPI criteria were compared to relevant UK clinical guidelines from the National 
Institute for Health and Care Excellence, the Scottish Intercollegiate Guideline Network and the 
British National Formulary for Children. Where guidelines differed, criteria were modified to 
reflect UK guidance. If there were no relevant guidelines or directly contradictory guidelines, 
criteria were removed. Overall, no change was made to 49 criteria. There were 29 modified to 
concord with UK guidelines. Four criteria were reduced to two criteria due to being linked in single 
guidelines. Twenty-three criteria were omitted, due to the absence of relevant UK guidance or 
directly conflicting UK practice, including one entire clinical category (mosquitos). One category 
title was amended to parallel UK terminology. The modified POPI (UK) tool comprises of eighty 
criteria and is the first rational prescribing tool for the evaluation of prescribing for children in 
hospital and outpatient settings in the UK. 
Keywords: paediatric; children; use of medicines; rational prescribing 
 
1. Introduction 
Rational prescribing describes practices aimed to optimise the use of medicines, encompassing 
safety, clinical effectiveness, access, and financial considerations. The WHO has defined rational 
prescribing as “when patients receive the appropriate medicines, in doses that meet their own 
individual requirements, for an adequate period of time, and at the lowest cost both to them and the 
community” [1]. Rational prescribing has been considered a problem mainly for low and lower 
middle-income countries, but it is increasingly being recognized as a problem in high-income 
countries [2,3]. 
Rational prescribing tools have been used, particularly in older adult medicine, as both research 
and quality improvement tools to investigate and improve rational prescribing [4]. These tools 
provide their users, whether individual prescribers, organizations, or research groups, with an 
objective measurement tool for the quality of prescribing according to rational prescribing 
principles. This facilitates research into factors involved in irrational prescribing, comparison across 
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time or between groups of prescribers, organizations, services, or geographical regions, and the 
assessment of the efficacy of quality improvement interventions. 
Children are a population particularly vulnerable to irrational prescribing due to the relative 
paucity of research supporting the paediatric use of medicines, with many medicines prescribed 
off-label, and children often excluded from drug trials. 
The Pediatrics: Omission of Prescriptions and Inappropriate Prescriptions (POPI) tool was 
published in 2013 [5]. It was the first rational prescribing tool for use in paediatrics worldwide. The 
tool comprises explicit criteria based on French, American, and UK guidelines. The selection of 
clinical indications was based upon French prevalence data and the criteria were selected by Delphi 
consensus. In total, there are 105 “propositions” in the POPI tool, which are either indicators of 
potentially inappropriate prescriptions (for example, ineffective treatments) or potentially 
inappropriate omissions (such as highly effective first-line treatments). 
Given the variation in the prevalence of disease, the availability of different formularies, and 
the diversity in paediatric practice internationally, the tool is not applicable outside of France. The 
only other extant rational prescribing tool for paediatric use is the potentially inappropriate 
prescribing in children (PIPc) indicators [6], which was developed exclusively for use in primary 
care settings. We therefore sought to modify the POPI tool for the application in UK paediatric 
practice in hospitals and outpatient settings by amending it to concord with UK clinical guidelines. 
The aims of our study were twofold. 
Firstly, to evaluate the applicability of the POPI tool to practice outside France by comparing 
the criteria to UK formulary and clinical guidelines. 
Secondly, to modify the tool, where necessary, for application to UK paediatric practice and 
therefore to facilitate further evaluation of the tool using UK prescribing data.  
2. Materials and Methods 
The 105 propositions of the POPI criteria were compared by one researcher (FC) to 
evidence-based UK clinical guidelines and clinical knowledge summaries from the National 
Institute of Health and Care Excellence (NICE) [7], the Scottish Intercollegiate Guidelines Network 
(SIGN) [8], the British National Formulary for Children (cBNF) [9], and the European Medicines 
Agency (EMA) [10]. The national guidance from NICE, SIGN and the cBNF were preferred; EMA 
recommendations were referred to when no national guidelines were available. This process used 
the most recent guidelines available on 1st October 2015. Where amendments were made, the 
specific related guideline is cited. 
Following the comparison with the guidelines, there were three possible outcomes: 
 Guidelines concurred with the POPI propositions. No change was made. 
 There was partial discordance. POPI propositions were amended to match UK guidance. 
 There was no guidance available or the proposition was in complete discordance with guidance, 
the proposition was omitted. 
The final wording of the modified POPI criteria was reached as consensus in consultation with 
two paediatric clinical pharmacology consultants. 
3. Results 
Overall, no change was made to 49 propositions. There were 29 amended to concord more 
closely with UK guidelines. Four were reduced into two propositions, as they were closely related 
and the relevant guidelines referred to them together, simplifying the tool. Twenty-three were 
omitted altogether, which included the omission of an entire category. One category title was 
amended, as the diagnosis of attention deficit disorder without hyperactivity is not in use in the UK.  
The most substantial single change was the omission of the category of “mosquitos”. There are 
currently no areas in the UK where insect-borne diseases are endemic. This was not considered 
applicable to UK practice and therefore the category comprising of seven propositions, was 
removed. Some suggest that the viable habitat of mosquito vectors for vivax malaria may expand to 
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the UK in the future, and if this were to occur, then this might be an appropriate area to target 
rational prescribing. 
Twelve propositions were omitted due to a lack of relevant clinical guidelines (Table 1). The 
majority of these related to inappropriate prescriptions for medicines that are either not used in the 
UK, e.g., Diosmectite, or not used by the rectal route, e.g., rectal paracetamol. 
Four propositions were also omitted where UK clinical guidelines contradicted the proposition. 
These are listed in Table 2 with the relevant conflicting UK guideline. They included the use of 
nitrofurantoin for urinary tract infections in young children; fluoride supplements in infants under 
the age of six months: the use of setrons (5-HT3 antagonists) for nausea/vomiting in association with 
chemotherapy; and isotretinoin for adolescent acne. 
Table 1. Propositions omitted due to the absence of relevant UK clinical guidelines. 
Symptom or Illness Category Omitted Paediatric Rational Prescribing Tool (POPI) Proposition 
Pain and fever (inappropriate 
prescriptions). 
Rectal administration of paracetamol as a first-line treatment. 
Pain and fever (omission). 
Failure to give sugar solution to newborn babies and infants under four 
months old two minutes prior to venipuncture. 
Urinary infection (inappropriate 
prescription). 
Nitrofurantoin used as a prophylactic. 
Diarrhoea (inappropriate 
prescription). 
The use of Diosmectite (Smecta) in combination with another medication 
[medication not approved for use in the UK]. 
The use of Saccharomyces boulardii (Ultralevure) in powder form, or in a 
capsule that has to be opened prior to ingestion, to treat patients with a 
central venous catheter or an immunodeficiency. 
Intestinal antiseptics. 
Cough (inappropriate 
prescription). 
Mucolytic drugs, mucokinetic drugs, or helicidine before two years of age. 
Alimemazine (Theralene), oxomemazine (Toplexil), promethazine 
(Phenergan, and other types). 
Terpene-based suppositories. 
Bronchiolitis (inappropriate 
prescription). 
0.9% NaCl to relieve nasal congestion (not applicable if nasal congestion is 
already being treated with 3% NaCl delivered by a nebulizer). 
ENT infections (inappropriate 
prescription). 
Ethanolamine tenoate (Rhinotrophyl) and other nasal antiseptics. 
Acne vulgaris (inappropriate 
prescription). 
Androgenic progestins (levonorgestrel, norgestrel, norethisterone, 
lynestrenol, dienogest, contraceptive implants or vaginal rings). 
Table 2. Propositions omitted due to conflicting UK clinical guidelines. 
Symptom or Illness Category Omitted POPI Proposition Conflicting UK Guideline 
Urinary infection 
(inappropriate prescription). 
Nitrofurantoin used as a 
curative agent in children 
under six years of age, or 
indeed any other antibiotic 
if avoidable. 
NICE guidance CG54: 
http://www.nice.org.uk/guidance/CG54/chapte
r/1-Guidance (Recommends nitrofurantoin for 
children aged three months and over.) 
Vitamin supplements and 
antibiotic prophylaxis 
(inappropriate prescription) 
Fluoride supplements prior 
to six months of age. 
SIGN guidance 138: 
http://www.sign.ac.uk/pdf/SIGN138.pdf 
(Describes risks and benefits as balanced.) 
NICE Delivering Better Oral Health Toolkit: 
http://www.nice.org.uk/guidance/ph55/chapte
r/context#delivering-better-oral-health-toolkit 
(Recommends fluoride toothpaste as soon as 
teeth erupt.) 
Nausea, vomiting, or 
gastroesophageal reflux 
(inappropriate prescription) 
The use of setrons (5-HT3 
antagonists) for 
chemotherapy-associated 
nausea and vomiting. 
British National Formulary for Children: 
https://bnfc.nice.org.uk/drug/ondansetron.htm
l (Chemotherapy-associated nausea and 
vomiting listed as licensed indication for 
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ondansetron.) 
Acne vulgaris (inappropriate 
prescription) 
Isotretinoin in combination 
with a member of the 
tetracycline family of 
antibiotics. 
NICE Acne Vulgaris Clinical Knowledge 
Summary: 
http://cks.nice.org.uk/acne-vulgaris#!topicsum
mary (Recommended second-line for moderate 
acne.) 
Two propositions were combined with closely related propositions, where the 
recommendations were linked in a single UK guideline in order to make the modified tool as concise 
as possible. The original and combined propositions are shown below in Table 3 with the related UK 
guidance. These related to the use of medicines for infants with bronchiolitis and the use of 
antibiotics in children with otitis media/upper respiratory tract infections. 
Table 3. Propositions with shared UK guidelines and the simplified combined proposition. 
Original POPI Propositions 
(Symptom or Illness Category) 
Relevant UK Guidance (NICE, SIGN or cBNF) 
Combined 
Proposition 
Beta2 agonists, corticosteroids to 
treat an infant’s first case of 
bronchiolitis. (Bronchiolitis in 
infants, inappropriate 
prescription.) 
NICE guidance NG9: 
http://www.nice.org.uk/guidance/ng9/chapter/1-Recom
mendations (Recommendation 1.4.3: Do not use any of 
the following to treat bronchiolitis in children: 
antibiotics; hypertonic saline; adrenaline (nebulised); 
salbutamol; montelukast; ipratropium bromide; 
systemic or inhaled corticosteroids; a combination of 
systemic corticosteroids and nebulised adrenaline.) 
(Inappropriate 
prescription) 
Antibiotics, Beta2 
agonists or 
corticosteroids to 
treat 
bronchiolitis. 
Antibiotics in the absence of 
signs indicating a bacterial 
infection (acute otitis media, 
fever, etc.). (Bronchiolitis in 
infants, inappropriate 
prescription.) 
An antibiotic other than 
amoxicillin as a first-line 
treatment for acute otitis media, 
strep throat, or sinusitis 
(provided that the patient is not 
allergic to amoxicillin). An 
effective dose of amoxicillin for 
a pneumococcal infection is 80–
90 mg/kg/day and an effective 
dose for a streptococcal infection 
is 50 mg/kg/day. (ENT 
infections, inappropriate 
prescription.) 
NICE guidance CG69: 
http://www.nice.org.uk/guidance/cg69/chapter/1-Guid
ance (A no antibiotic prescribing strategy or a delayed 
antibiotic prescribing strategy should be agreed upon 
for patients with the following conditions: acute otitis 
media; acute sore throat/acute pharyngitis/acute 
tonsillitis; common cold; acute rhinosinusitis; acute 
cough/acute bronchitis. 
Depending on the clinical assessment of severity, 
patients in the following subgroups can also be 
considered for an immediate antibiotic prescribing 
strategy (in addition to a no antibiotic or a delayed 
antibiotic prescribing strategy): Bilateral acute otitis 
media in children younger than two years; acute otitis 
media in children with otorrhoea; acute sore 
throat/acute pharyngitis/acute tonsillitis when three or 
more Centor criteria are present. 
SIGN guideline 117: In severe cases, where the 
practitioner is concerned about the clinical condition of 
the patient, antibiotics should not be withheld. 
(Penicillin V 500 mg four times daily for 10 days is the 
dosage used in the majority of studies. A macrolide can 
be considered as an alternative first line treatment, in 
line with local guidance.) 
(Inappropriate 
prescription) An 
antibiotic for <4 
days symptoms 
of acute upper 
respiratory tract 
infection (except: 
bilateral acute 
otitis media in 
children younger 
than two years; 
acute otitis media 
in children with 
otorrhoea; acute 
sore throat/acute 
pharyngitis/acute 
tonsillitis when 
three or more 
Centor criteria 
are present). 
Antibiotics for nasopharyngitis, 
congestive otitis, sore throat 
before three years of age, or 
laryngitis; antibiotics as a 
first-line treatment for acute 
otitis media showing few 
symptoms, before two years of 
age. (ENT infections, 
inappropriate prescription.) 
There were 19 propositions that related to inappropriate prescriptions, and 10 propositions that 
related to inappropriate omissions that were amended to more closely concord with UK guidelines 
(Table 4 and Table 5). In some instances, the age was changed, e.g., loperamide is considered 
inappropriate in the UK in children under the age of four years old, whereas in France it is under the 
Healthcare 2019, 7, 33 5 of 15 
 
age of three years old. Some medicines such as benzyl benzoate are not recommended at all in 
children in the UK. Some medicines such as sodium cromoglycate are not recommended at all in 
France, whereas in the UK it can be used for exercise-induced asthma. In addition, the category title 
of “Attention deficit disorder with or without hyperactivity” was amended to “Attention deficit 
hyperactivity disorder”, as attention deficit disorder without hyperactivity is not recognised in UK 
clinical guidelines. 
Others involved minor changes in relation to dosing and age for penicillin prophylaxis for 
children with sickle cell disease; patient groups for palivizumab: or vitamin use in infants. 
Table 4. Inappropriate prescription propositions modified to concord with UK guidelines. 
Original POPI 
Propositions—Inappr
opriate Prescription 
(Symptom or Illness 
Category) 
Relevant UK Guidance (NICE, SIGN or cBNF) 
(Recommendation) 
Modified POPI 
Proposition—Ina
ppropriate 
Prescription 
Prescription of a 
medication other than 
paracetamol as a 
first-line treatment [for 
pain] (except in the 
case of migraine). (Pain 
and fever) 
NICE Clinical Knowledge Summary: Management of 
mild-to-moderate pain: 
http://cks.nice.org.uk/analgesia-mild-to-moderate-pain#!scenar
io (Prescribe either paracetamol or ibuprofen alone. Both are 
suitable first-line choices for treating mild-to-moderate pain in 
children.) 
Prescription of a 
medication other 
than paracetamol 
or ibuprofen as a 
first-line treatment 
for pain (except in 
the case of a 
migraine). 
Oral solutions of 
ibuprofen 
administered in more 
than three doses per 
day using a graduated 
pipette of 10 mg/kg 
(other than Advil). 
(Pain and fever) 
cBNF Ibuprofen: https://bnfc.nice.org.uk/drug/ibuprofen.html 
(Child 1–3 months 5 mg/kg 3–4 times daily. Child 3–6 months 50 
mg 3 times daily; max. 30 mg/kg daily in 3–4 divided doses. 
Child 6 months to 1 year 50 mg 3–4 times daily; max. 30 mg/kg 
daily in 3–4 divided doses. Child 1–4 years 100 mg 3 times daily; 
max. 30 mg/kg daily in 3–4 divided doses. Child 4–7 years 150 
mg 3 times daily; max. 30 mg/kg daily in 3–4 divided doses. 
Child 7–10 years old 200 mg 3 times daily; max. 30 mg/kg (max. 
2.4 g) daily in 3–4 divided doses. Child 10–12 years 300 mg 3 
times daily; max. 30 mg/kg (max. 2.4 g) daily in 3–4 divided 
doses. Child 12–18 years initially 300–400 mg 3–4 times daily; 
increased if necessary to max. 600 mg four times daily; 
maintenance dose of 200–400 mg three times daily may be 
adequate.) 
Doses of ibuprofen 
administered in 
more than three 
doses per day or 
exceeding 
maximum dose of 
30 mg/kg daily in 
three doses per 
day. 
Gastric antisecretory 
drugs to treat 
gastroesophageal 
reflux, dyspepsia, the 
crying of newborn 
babies (in the absence 
of any other signs or 
symptoms), as well as 
faintness in infants. 
(Nausea, vomiting, or 
gastroesophageal 
reflux) 
NICE guidance NG1: 
http://www.nice.org.uk/guidance/NG1/chapter/1-Recommend
ations (Recommendation 1.3.1: Do not offer acid-suppressing 
drugs, such as proton pump inhibitors (PPIs) or H2 receptor 
antagonists (H2RAs), to treat overt regurgitation in infants and 
children occurring as an isolated symptom.  
Recommendation 1.3.2: Consider a four-week trial of a PPI or 
H2RA for those who are unable to tell you about their 
symptoms (for example, infants and young children, and those 
with a neurodisability associated with expressive 
communication difficulties) who have overt regurgitation with 
one or more of the following: unexplained feeding difficulties 
(for example, refusing feeds, gagging or choking); distressed 
behaviour; faltering growth.) 
Acid-suppressing 
drugs to treat 
overt 
regurgitation in 
the absence of 
feeding 
difficulties, 
distress, or 
faltering growth. 
The use of type H2 
antihistamines for long 
periods of treatment. 
(Nausea, vomiting, or 
gastroesophageal 
reflux) 
NICE guidance NG1: 
http://www.nice.org.uk/guidance/NG1/chapter/1-Recommend
ations (Recommendation 1.3.4: four-week trial then stop, assess 
response, refer if symptoms recur.) 
The use of H2 
receptor 
antagonists for 
more than four 
weeks. 
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Erythromycin as a 
prokinetic agent. 
(Nausea, vomiting, or 
gastroesophageal 
reflux) 
NICE guidance NG1: 
http://www.nice.org.uk/guidance/NG1/chapter/1-Recommend
ations (Do not offer metoclopramide, domperidone or 
erythromycin without seeking specialist advice.) 
Erythromycin. 
Loperamide before 
three years of age. 
(Diarrhoea) 
cBNF Loperamide: 
https://bnfc.nice.org.uk/drug/loperamide-hydrochloride.html 
(Licensed from four years.) 
Loperamide 
before four years 
of age 
Antibiotic treatment 
for a sore throat, 
without a positive 
rapid diagnostic test 
result, in children less 
than three years old. 
(ENT infections) 
SIGN guideline 117: 
http://www.sign.ac.uk/guidelines/fulltext/117/ (Minimises 
usefulness of rapid diagnostic test results in guiding therapy: 
In severe cases, where the practitioner is concerned about the 
clinical condition of the patient, antibiotics should not be 
withheld. (Penicillin V 500 mg four times daily for 10 days is 
the dosage used in the majority of studies. A macrolide can be 
considered as an alternative first-line treatment, in line with 
local guidance.) 
Antibiotic 
treatment for a 
sore throat except 
in severe cases 
(where the 
patient’s clinical 
condition is 
documented as 
concerning). 
Antibiotics to treat 
otitis media with 
effusion (OME), except 
in the case of hearing 
loss or if OME lasts for 
more than three 
months. (ENT 
infections) 
NICE Clinical Knowledge Summary: 
http://cks.nice.org.uk/otitis-media-with-effusion#!scenario 
(Period of active observation for 6–12 weeks: During this 
period, do not prescribe antibiotics, steroids, antihistamines, 
decongestants, or mucolytics specifically for the treatment of 
otitis media with effusion (OME).) 
Antibiotics to treat 
otitis media with 
effusion in the first 
6–12 weeks. 
H1-antagonists with 
sedative or 
atropine-like effects 
(pheniramine, 
chlorpheniramine), or 
camphor; inhalers, 
nasal sprays, or 
suppositories 
containing menthol (or 
any terpene 
derivatives) before 30 
months of age. (ENT 
infections) 
cBNF: 
https://www.evidence.nhs.uk/formulary/bnfc/current/3-respira
tory-system/34-antihistamines-immunotherapy-and-allergic-e
mergencies/341-antihistamines#PHP11980 (Sedating 
antihistamines not for use in neonates, phenothiazine sedating 
antihistamines not for use <2 years, chlorphenamine not 
licensed <1 year.) 
https://www.evidence.nhs.uk/formulary/bnfc/current/3-respira
tory-system/38-aromatic-inhalations (Menthol inhalations 
permissible, no sprays or suppositories in BNF nor terpene 
containing medicines.) 
Sedating 
antihistamines 
(pheniramine, 
chlorpheniramine) 
before two years 
(except for 
anaphylaxis). 
Ketotifen and other 
H1-antagonists, 
sodium cromoglycate. 
(Asthma) 
SIGN guidance 141 (British guideline on the management of 
asthma): http://www.sign.ac.uk/pdf/SIGN141.pdf 
(Antihistamines and ketotifen are ineffective. Sodium 
cromoglycate for exercise-induced asthma.) 
Ketotifen and 
other 
antihistamines. 
The application of 
benzyl benzoate 
(Ascabiol) for periods 
longer than eight hours 
for infants and 12 h for 
children or for 
pregnant girls. 
(Scabies) 
Children’s BNF: 
http://www.evidence.nhs.uk/formulary/bnf/current/13-skin/13
10-anti-infective-skin-preparations/13104-parasiticidal-prepara
tions/scabies 
and NICE Clinical Knowledge Summary: 
http://cks.nice.org.uk/scabies#!scenario (Benzyl benzoate 
should be avoided in children (permethrin or malathion are 
less irritant and more effective and should be used instead.) 
Benzyl benzoate. 
Treatment other than 
griseofulvin for 
Microsporum. 
(Ringworm) 
NICE Clinical Knowledge Summary Fungal Skin infections: 
http://cks.nice.org.uk/fungal-skin-infection-body-and-groin#!sc
enario (Recommends topical treatment first-line. Gruseofulvin 
the only oral treatment appropriate for children.) 
Oral treatment 
other than 
griseofulvin. 
Any antibiotic other 
than mupirocin as a 
first-line treatment 
(except in cases of 
NICE Clinical Knowledge Summary Impetigo: 
http://cks.nice.org.uk/impetigo#!scenario (For localized [sic] 
infection, treat with topical fusidic acid… Topical mupirocin, 
retapamulin, and antiseptics are not recommended initially.) 
Any antibiotic 
other than fusidic 
acid as a first-line 
treatment (except 
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hypersensitivity to 
mupirocin). (Impetigo) 
in cases of 
hypersensitivity to 
fusidic acid). 
Orally administered 
acyclovir to treat 
primary herpetic 
gingivostomatitis. 
(Herpes simplex) 
NICE Clinical Knowledge Summary Herpes Simplex (oral): 
http://cks.nice.org.uk/herpes-simplex-oral#!scenario:1 
(Consider oral antivirals for immunocompetent individuals 
with severe gingivostomatitis.) 
Orally 
administered 
aciclovir to treat 
severe herpetic 
gingivostomatitis. 
A strong 
dermocorticoid 
(clobetasol propionate 
0.05% Dermoval, 
betamethasone 
dipropionate 
Diprosone) applied to 
the face, the armpits or 
groin, and the backside 
of babies or young 
children. (Atopic 
eczema) 
NICE guidance CG57: 
https://www.nice.org.uk/guidance/CG57/chapter/1-Guidance 
(use mild potency for the face and neck, except for short-term 
(3–5 days) use of moderate potency for severe flares; use 
moderate or potent preparations for short periods only (7–14 
days) for flares in vulnerable sites such as axillae and groin; do 
not use very potent preparations in children without specialist 
dermatological advice.) 
Children’s BNF Dermoval not listed: 
http://www.evidence.nhs.uk/formulary/bnf/current/13-skin/13
4-topical-corticosteroids/topical-corticosteroid-preparation-pot
encies 
A potent topical 
corticosteroid 
applied to the face, 
or for >14 days 
applied to the 
axilla or groin. 
Local or systemic 
antihistamine during 
the treatment of 
outbreaks. (Atopic 
eczema) 
NICE guidance CG57: 
https://www.nice.org.uk/guidance/CG57/chapter/1-Guidance 
(Recommendation 1.5.6: Healthcare professionals should offer a 
1-month trial of a non-sedating antihistamine to children with 
severe atopic eczema or children with mild or moderate atopic 
eczema where there is severe itching or urticaria. Healthcare 
professionals should offer a 7–14 day trial of an age-appropriate 
sedating antihistamine to children aged 6 months or over during 
an acute flare of atopic eczema if sleep disturbance has a 
significant impact on the child or parents or carers.) 
Prescription of 
antihistamines 
except as a trial for 
severe itching or 
where sleep 
disturbance has a 
significant impact 
on the child or 
carers. 
Cyproheptadine 
(Perlactin), clonidine. 
(Anorexia) 
NICE guidance CG9: 
https://www.nice.org.uk/guidance/CG9/chapter/1-Guidance 
(Recommendation 1.2.3.1: Medication should not be used as the 
sole or primary treatment for anorexia nervosa.) 
Prescription of 
medications as a 
sole or primary 
treatment for 
anorexia nervosa. 
Antipsychotic drugs to 
treat attention deficit 
disorder without 
hyperactivity. 
(attention deficit 
disorder with or 
without hyperactivity) 
NICE guidance CF72: 
https://www.nice.org.uk/guidance/cg72/chapter/1-Guidance 
(Recommendation 1.5.5.7: Antipsychotics are not 
recommended for the treatment of ADHD in children and 
young people.) 
Antipsychotic 
drugs to treat 
attention deficit 
hyperactivity 
disorder. 
Slow release 
methylphenidate as 
two doses per day, 
rather than only one 
dose. (Attention deficit 
disorder with or 
without hyperactivity) 
NICE guidance CF72: 
https://www.nice.org.uk/guidance/cg72/chapter/1-Guidance 
(Recommendation 1.8.2.2: modified-release preparations 
should be given as a single dose in the morning.) 
Modified release 
methylphenidate 
as two doses per 
day rather than 
only one dose. 
Table 5. Omission of prescription propositions modified to concord with UK guidelines. 
Original POPI Propositions— 
Inappropriate Omission 
(Symptom or Illness Category) 
Relevant UK Guidance (NICE, SIGN or 
cBNF) (Recommendation) 
Modified POPI 
Proposition—Inappropriate 
Omission 
Insufficient intake of vitamin D. 
Minimum vitamin D intake: 
Breastfed baby = 1000 to 1200 
NICE guidance PH56: 
http://www.nice.org.uk/guidance/ph56/cha
pter/1-Recommendations (Vitamin D 
Healthy Start vitamins for 
infants and children 0.5–5 
years or having less than 500 
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IU/day; Infant, 18 months of age 
(milk enriched in vitamin D) = 
600–800 IU/day; Child aged 
between 18 months and five 
years, and adolescents aged 
between 10 and 18 years: two 
quarterly loading doses of 80,000 
to 100,000 IU/day in winter 
(adolescents can take this dose in 
one go). (Vitamin supplements 
and antibiotic prophylaxis) 
supplements should be available for at-risk 
groups, including infants and children <5 
years, Healthy Start vitamins.) 
mL infant formula per day. 
Antibiotic prophylaxis with 
phenoxymethylpenicillin 
(Oracilline) starting from two 
months of age and lasting until 
five years of age for children 
with sickle-cell anaemia: 100,000 
IU/kg/day (in two doses) for 
children weighing 10kg or less 
and 50,000 IU/kg/day for 
children weighing over 10 kg 
(also in two doses). (Vitamin 
supplements and antibiotic 
prophylaxis) 
NICE Clinical Knowledge Summary: 
http://cks.nice.org.uk/sickle-cell-disease#!sc
enario:3 (Explain that lifelong prophylaxis 
is recommended, but it is particularly 
important that there is full adherence up to 
five years of age.  
Prescribe phenoxymethylpenicillin 
(penicillin V) prophylaxis from the age of 
one month, at a dose of: 125 mg twice a day 
for infants and children up to five years of 
age. 250 mg twice a day for children from 
six to 12 years of age. 500 mg twice a day 
for adults and children older than 12 years 
of age.  
Erythromycin is recommended for people 
who are allergic to penicillin, at a dose of: 
125 mg twice a day for infants and children 
up to two years of age. 250 mg twice a day 
for adults and children older than two 
years of age.) 
Antibiotic prophylaxis with 
phenoxyethylpenicillin 
(penicillin V) from age one 
month until five years old for 
children with sickle-cell 
anaemia at a dose of: 125 mg 
twice a day for infants and 
children up to five years of 
age. 250 mg twice a day for 
children from six to 12 years 
of age. 500 mg twice a day for 
adults and children older 
than 12 years of age.  
Or Erythromycin for children 
who are allergic to penicillin, 
at a dose of: 125 mg twice a 
day for infants and children 
up to two years of age. 250 
mg twice a day for children 
older than two years of age. 
Oral rehydration solution. 
(Nausea, vomiting, or 
gastroesophageal reflux) 
NICE guidance CG84: 
http://www.nice.org.uk/guidance/cg84/cha
pter/1-Guidance#fluid-management (Offer 
ORS solution as supplemental fluid to 
children at risk of dehydration or use in 
dehydrated children unless IV fluid is 
indicated.) 
Amend: Oral rehydration 
solution for dehydrated 
children unless IV fluid 
therapy is indicated (shock, 
red flag symptoms despite 
ORS, persist vomiting of 
ORS). 
Oral rehydration solution. 
(Diarrhoea) 
NICE guidance CG84: 
http://www.nice.org.uk/guidance/cg84/cha
pter/1-Guidance#fluid-management (Offer 
ORS solution as supplemental fluid to 
children at risk of dehydration or use in 
dehydrated children unless IV fluid is 
indicated.) 
Amend: Oral rehydration 
solution for dehydrated 
children unless IV fluid 
therapy is indicated (shock, 
red flag symptoms despite 
ORS, persistent vomiting of 
ORS). 
Failure to propose a whooping 
cough booster vaccine for adults 
who are likely to become parents 
in the coming months or years 
(only applicable if the previous 
vaccination was more than 10 
years ago). This booster 
vaccination should also be 
proposed to the family and 
entourage of expectant parents 
(parents, grandparents, 
nannies/child minders). 
(Cough). 
NICE CKS Antenatal care of uncomplicated 
pregnancy: 
http://cks.nice.org.uk/antenatal-care-unco
mplicated-pregnancy#!scenario (28 weeks 
gestation: Offer vaccination against 
pertussis.) 
Amend: Failure to propose a 
whooping cough vaccine for 
pregnant women. 
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Palivizumab in the following 
cases: (1) babies born both at less 
than 35 weeks of gestation and 
less than six months prior to the 
onset of a seasonal RSV epidemic; 
(2) children less than two years 
old who have received treatment 
for bronchopulmonary dysplasia 
in the past six months; (3) 
children less than two years old 
suffering from congenital heart 
disease with hemodynamic 
abnormalities. (Bronchiolitis in 
infants). 
SIGN guidance 91 (Bronchiolitis in children): 
http://www.sign.ac.uk/guidelines/fulltext/91
/index.html (… recommends use of 
palivizumab in high risk groups, as defined 
by the committee (children under two years 
of age with chronic lung disease, on home 
oxygen or who have had prolonged use of 
oxygen; infants less than six months of age 
who have left to right shunt 
haemodynamically significant congenital 
heart disease and/or pulmonary 
hypertension; children under two years of 
age with severe congenital 
immuno-deficiency).) 
Amend: Palivizumab in 
high-risk cases, defined as: 
children <2 years with 
chronic lung disease on 
home oxygen or who have 
prolonged use of oxygen; 
infants <6 months with 
left-to-right shunt 
haemodynamically 
significant congenital heart 
disease and/or pulmonary 
hypertension; children <2 
years with severe congenital 
immunodeficiency.) 
Asthma inhaler appropriate for 
the child’s age. (Asthma) 
NICE guidance TA10: 
https://www.nice.org.uk/guidance/ta10 
(NICE has recommended that for children 
under the age of five years who have 
chronic stable asthma: both corticosteroids 
and bronchodilator therapy should 
routinely be delivered by Pressurised 
Metered Dose Inhaler (pMDI) and spacer 
system, with a facemask where necessary. 
Where this combination is not clinically 
effective for the child, and depending on 
the child’s condition, nebulised therapy 
may be considered and in the case of 
children aged 3–5 years, a dry powder 
inhaler (DPI) may also be considered. The 
choice of which pMDI device and spacer to 
use should be determined by the specific 
needs of the child and how well it works for 
them. Once these factors have been taken 
into account the choice should be made on 
the basis of reducing costs.) 
Amend: Asthma inhaler 
appropriate for the child’s 
age (aged <5 years, either 
Metered Dose Inhaler with 
spacer system or nebuliser; 
age 3–5 years Dry Powder 
Inhaler may be appropriate). 
Contraception (provided with a 
logbook/diary) for menstruating 
girls taking isotretinoin. (Acne 
vulgaris) 
Children’s BNF: 
https://www.evidence.nhs.uk/formulary/b
nf/current/13-skin/136-acne-and-rosacea/13
62-oral-preparations-for-acne/oral-retinoid-
for-acne/isotretinoin (Effective 
contraception must be used.) 
Amend: Contraception for 
menstruating girls taking 
isotretinoin. 
A second dose of ivermectin two 
weeks after the first. (Scabies) 
Children’s BNF: 
https://bnfc.nice.org.uk/treatment-summar
y/skin-infections.html (Ivermectin only 
available by special order, unlicensed for 
scabies.) 
https://bnfc.nice.org.uk/drug/permethrin.ht
ml 
https://bnfc.nice.org.uk/drug/malathion.ht
ml (Apply once weekly for two doses.) 
Amend: A second 
application of permethrin or 
malathion one week after the 
first. 
Decontamination of household 
linen and clothes and treatment 
for other family members. 
(Scabies) 
NICE Clinical Knowledge Summary: 
http://cks.nice.org.uk/scabies#!scenario 
(Decontamination of household linen and 
clothes and same day treatment of all 
members of the household.) 
Amend: Decontamination of 
household linen and clothes 
and same day treatment of 
all members of the 
household. 
The resulting modified POPI criteria therefore comprise 80 propositions assessing rational 
prescribing for children in accordance with up-to-date UK guidelines (see Table 6). 
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Table 6. The modified POPI (UK) tool. 
DIVERSE ILLNESSES 
PAIN AND FEVER 
Inappropriate prescriptions. 
Prescription of two alternating antipyretics as a first-line treatment. 
Prescription of a medication other than paracetamol or ibuprofen as a first-line treatment for pain (except in the 
case of a migraine). 
The combined use of two NSAIDs. 
Doses of ibuprofen administered in more than three doses per day or exceeding maximum dose of 30 mg/kg 
daily in three doses per day. 
Opiates to treat migraine attacks. 
Omissions. 
Failure to give an osmotic laxative to patients being treated with morphine for a period of more than 48 h. 
URINARY INFECTIONS 
Inappropriate prescriptions. 
Antibiotic prophylaxis following an initial infection without complications (except in the case of uropathy). 
Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of uropathy). 
VITAMIN SUPPLEMENTS AND ANTIBIOTIC PROPHYLAXIS 
Omissions. 
Healthy Start vitamins for infants and children 0.5–5 years or having less than 500 mL infant formula per day. 
Antibiotic prophylaxis with phenoxyethylpenicillin (penicillin V) from age one month until five years for 
children with sickle-cell anaemia at a dose of: 
 125 mg twice a day for infants and children up to five years of age. 
 250 mg twice a day for children from six to 12 years of age. 
 500 mg twice a day for adults and children older than 12 years of age. 
Or Erythromycin for children who are allergic to penicillin, at a dose of: 
 125 mg twice a day for infants and children up to two years of age. 
 250 mg twice a day for children older than two years of age. 
DIGESTIVE PROBLEMS 
NAUSEA, VOMITING, OR GASTROESOPHAGEAL REFLUX 
Inappropriate prescriptions. 
Metoclopramide. 
Domperidone. 
Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube). 
Acid-suppressing drugs to treat overt regurgitation in the absence of feeding difficulties, distress, or faltering 
growth. 
The combined use of proton pump inhibitors and NSAIDs, for a short period of time, in patients without risk 
factors. 
The use of H2 receptor antagonists for more than four weeks. 
Erythromycin. 
Omissions. 
Oral rehydration solution (ORS) for dehydrated children unless IV fluid therapy is indicated (shock, red flag 
symptoms despite ORS, persist vomiting of ORS). 
DIARRHOEA 
Inappropriate prescriptions. 
Loperamide before four years of age. 
Loperamide in the case of invasive diarrhoea. 
Omissions. 
Oral rehydration solution (ORS) for dehydrated children unless IV fluid therapy is indicated (shock, red flag 
symptoms despite ORS, persist vomiting of ORS). 
ENT-PULMONARY PROBLEMS 
COUGH 
Inappropriate prescriptions. 
Pholcodine. 
Omissions. 
Failure to propose a whooping cough vaccine for pregnant women. 
BRONCHIOLITIS IN INFANTS 
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Inappropriate prescriptions. 
Antibiotics, Beta2 agonists or corticosteroids to treat bronchiolitis. 
H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis. 
Omissions. 
Palivizumab in high-risk cases, defined as: 
 Children <2 years with chronic lung disease on home oxygen or who have prolonged use of oxygen; 
 Infants <6 months with left-to-right shunt haemodynamically significant congenital heart disease and/or 
pulmonary hypertension; 
 Children <2 years with severe congenital immunodeficiency. 
ENT INFECTIONS 
Inappropriate prescriptions. 
An antibiotic for <4 days symptoms of acute upper respiratory tract infection (except: 
 Bilateral acute otitis media in children younger than two years; 
 Acute otitis media in children with otorrhoea; 
 Acute sore throat/acute pharyngitis/acute tonsillitis when three or more Centor criteria are present.) 
Antibiotic treatment for a sore throat except in severe cases (anticipated to be no more than 20% of cases). 
Antibiotics to treat otitis media with effusion in the first 6–12 weeks. 
Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat. 
Nasal or oral decongestant (oxymetazoline (Aturgyl), pseudoephedrine (Sudafed), naphazoline (Derinox), 
ephedrine (Rhinamide), tuaminoheptane (Rhinofluimicil), phenylephrine (Humoxal)). 
Sedating antihistamines (pheniramine, chlorpheniramine) before two years (except for anaphylaxis). 
Eardrops in the case of acute otitis media. 
Omissions. 
Doses in mg for drinkable (solutions of) amoxicillin or josamycin. 
Paracetamol combined with antibiotic treatment for ear infections to relieve pain. 
ASTHMA 
Inappropriate prescriptions. 
Ketotifen and other antihistamines. 
Cough suppressants. 
Omissions. 
Asthma inhaler appropriate for the child’s age (aged <5 years, either Metered Dose Inhaler with spacer system 
or nebuliser; age 3–5 years Dry Powder Inhaler may be appropriate). 
Preventative treatment (inhaled corticosteroids) in the case of persistent asthma. 
DERMATOLOGICAL PROBLEMS 
ACNE VULGARIS 
Inappropriate prescriptions. 
Minocycline. 
The combined use of an oral and a local antibiotic. 
Oral or local antibiotics as a monotherapy (not in combination with another drug). 
Cyproterone + ethinylestradiol (Diane 35) as a contraceptive to allow isotretinoin per os. 
Omissions. 
Contraception for menstruating girls taking isotretinoin. 
Topical treatment (benzoyl peroxide, retinoids, or both) in combination with antibiotic therapy. 
SCABIES 
Inappropriate prescriptions. 
Benzyl benzoate. 
Omissions. 
A second application of permethrin or malathion one week after the first. 
Decontamination of household linen and clothes and same day treatment of all members of the household. 
LICE 
Inappropriate prescriptions. 
The use of aerosols for infants, children with asthma, or children showing asthma-like symptoms such as dyspnea. 
RINGWORM 
Inappropriate prescriptions. 
Oral treatment other than griseofulvin. 
Omissions. 
Topical treatment combined with an orally administered treatment. 
Griseofulvin taken during a meal containing a moderate amount of fat. 
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IMPETIGO 
Inappropriate prescriptions. 
The combination of a locally applied and orally administered antibiotic. 
Fewer than two applications per day for topical antibiotics. 
Any antibiotic other than fusidic acid as a first-line treatment (except in cases of hypersensitivity to fusidic acid). 
HERPES SIMPLEX 
Inappropriate prescriptions. 
Topical agents containing corticosteroids. 
Topical agents containing aciclovir before six years of age. 
Omissions. 
Paracetamol during an outbreak of herpes. 
Orally administered aciclovir to treat severe herpetic gingivostomatitis. 
ATOPIC ECZEMA 
Inappropriate prescriptions. 
A potent topical corticosteroid applied to the face, or for >14 days applied to the axilla or groin. 
More than one application per day of a dermocorticoid, except in cases of severe lichenification. 
Prescription of antihistamines except as a trial for severe itching or where sleep disturbance has a significant 
impact on the child or carers. 
Topically applied 0.03% tacrolimus before two years of age. 
Topically applied 0.1% tacrolimus before 16 years of age. 
Oral corticosteroids to treat outbreaks. 
NEUROPSYCHIATRIC DISORDERS 
EPILEPSY 
Inappropriate prescriptions. 
Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of 
myoclonic epilepsy. 
Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of 
epilepsy with absence seizures (especially for childhood absence epilepsy or juvenile absence epilepsy). 
Levetiracetam, oxcarbamazepine in mL or in mg without systematically writing XX mg per Y mL. 
DEPRESSION 
Inappropriate prescriptions. 
An SSRI antidepressant other than fluoxetine as a first-line treatment (in the case of pharmacotherapy). 
Tricyclic antidepressants to treat depression. 
NOCTURNAL ENURESIS 
Inappropriate prescriptions. 
Desmopressin administered by a nasal spray. 
Desmopressin in the case of d`aytime symptoms. 
An anticholinergic agent used as a monotherapy in the absence of daytime symptoms. 
Tricyclic agents in combination with anticholinergic agents. 
Tricyclic agents as a first-line treatment. 
ANOREXIA 
Inappropriate prescriptions. 
Prescription of medications as a sole or primary treatment for anorexia nervosa. 
ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY 
Inappropriate prescriptions. 
Pharmacological treatment before age six (before school), except in severe cases. 
Antipsychotic drugs to treat attention deficit hyperactivity disorder. 
Modified release methylphenidate as two doses per day, rather than only one dose. 
Omissions. 
Recording a growth chart (height and weight) if the patient is taking methylphenidate. 
4. Discussion 
The POPI criteria were modified to develop a list of potentially inappropriate prescriptions and 
omissions for children in the UK. 
Over half of the propositions of the POPI criteria were altered. The majority of those changes 
were subtle modifications to bring the wording of propositions more closely in line with the specific 
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wording of UK clinical guidelines. In other cases, the propositions were directly in contradiction of 
relevant guidelines and were amended accordingly. In order for this tool to be useful in appraising 
rational prescribing in the UK, it is important that prescribers are being measured against the 
specific standards they are striving for, and this would also facilitate straightforward interventions 
using UK guidelines for education and service improvement. 
For 22 propositions, there were no relevant UK clinical guidelines. Absence from guidelines 
does not necessarily invalidate the recommendations of those propositions but the propositions 
were omitted, as they appeared to relate to the irrational use of medicines that do not appear to be 
prevalent in the UK. In some cases, the propositions related to medications not available in the UK. 
For instance, in the case of diosmectite for diarrhoea, there is some emerging evidence supporting its 
use [11] but this is not reflected in the availability of the product in the UK.  
In other cases, differing national practices may explain the absence if the type of irrational 
prescribing described is already rare in UK practise. This explanation likely underlies guidance 
about rectally administered drugs including paracetamol per rectum for pain and suppositories for 
cough. The cultural difference that may give rise to this variance in clinical practice was recognised 
in the European Medicines Agency Guideline on pharmaceutical development of medicines for 
paediatric use [12] when discussing medication acceptability in different countries, giving the 
example that “the rectal route of administration is not generally favoured in the UK”. 
Two of the omitted propositions, in relation to sucrose for painful procedures in infants and 
nitrofurantoin as prophylaxis for urinary infection, may be absent from national UK guidelines 
because these are areas where there is not a national consensus of best practice. In reviewing these 
topics, local guidelines were found to differ, including some recommending nitrofurantoin for that 
purpose [13,14] and some preferring breast or bottle-feeding over sucrose, recommending 
contraindications and qualifying the guideline according to gestation and the age of the infant 
[15,16]. In the absence of a unifying national guideline on these topics, they were therefore not 
considered to be good candidates for screening prescribing practice nationally. 
Four propositions were omitted due to the existence of UK clinical guidelines that were in 
direct conflict with the original proposition (see Table 2).  
Three of these appear to have been included as potentially inappropriate prescriptions in the 
original French tool due to the risk of interactions or side effects. One related to nitrofurantoin for 
the treatment of urinary infections. According to the report describing the development of the 
original POPI tool, this proposition was derived from a statement issued by AFSSAPS (the French 
Agency for the Safety of Health Products, Agence Française de Sécurité Sanitaire des Produits de 
Santé) in 2011, warning of cases of severe hepatic and pulmonary complications following long-term 
treatment with nitrofurantoin [17].  
The cBNF does recommend monitoring liver function and for pulmonary symptoms if 
prescribing nitrofurantoin long-term, but it is licensed and indicated in acute uncomplicated urinary 
tract infections for children aged three months and older [9] and is second-line for children aged 
three months and older in the most recent NICE guideline NG109 [7].  
The second related to isotretinoin and tetracycline antibiotics. This appears to be derived from a 
Good Practice Recommendation from AFSSAP describing isotretinoin as contraindicated with 
tetracyclines due to the reported occurrence of benign intracranial hyptertension with this 
combination [18]. This risk is recorded in the cBNF as a possible interaction, rated as “serious” with 
an anecdotal evidence base [9]. The combination is not recorded as a contraindication and combined 
topical retinoids and oral tetracyclines and recommended in the NICE Clinical Knowledge 
Summary.  
The third related to fluoride supplements before age six months. The related French guideline, 
an AFSAPPS statement in 2008, recommended that fluoride containing supplements such as 
toothpaste, commence when teeth erupt, on average at age six months [19]. This statement, like the 
relevant UK guidelines, discusses the risk of dental fluorosis with excess fluoride consumption 
during tooth development and recommends lower dose fluoride in toothpaste for young children. 
Both the NICE and SIGN guidelines quoted in Table 2 acknowledge the risk of dental fluorosis and 
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state that the benefit of reduced caries favours starting fluoride supplementation as soon as teeth 
erupt with no definitive lower age limit of benefit to the child. 
These all appear to reflect differing risk tolerance between the French and UK guidelines. In 
order that the modified tool reflects what is considered nationally to be good practice, the 
propositions were therefore omitted from the modified tool. 
The fourth omitted proposition listed, “The use of setrons (5-HT3 antagonists) for 
chemotherapy-associated nausea and vomiting”, as a potentially inappropriate prescription. It was 
not clear what evidence was used to develop this proposition as none of the references in the report 
describing the development of the original tool related to chemotherapy-associated nausea and 
vomiting. One reference from the American Centers for Disease Control and Prevention 
recommended ondansetron as an anti-emetic for children [20]. It is possible that the inclusion of this 
criterion in the original tool constitutes a typographical error, and that it was intended to read as an 
inappropriate omission, given the importance of treating chemotherapy-associated nausea. It was 
therefore felt not to accurately reflect rational prescribing and was omitted from the modified tool. 
Following the described amendments, the modified POPI(UK) tool comprises eighty criteria 
describing potentially inappropriate prescriptions or omissions. This tool is intended to evaluate the 
quality of prescribing for children in both hospital and outpatient settings, and is not limited to a 
specific group of prescribers. Similar tools for evaluating rational prescribing for older adults have 
facilitated a broad range of research, including research into quality of prescribing across different 
settings [21], studies into healthcare outcomes associated with irrational prescribing [22], and to 
predict adverse health outcomes in patient groups [23]. The tool is not intended for routine use by 
individual prescribers, as it requires experience to use. 
5. Conclusions 
The modified POPI (UK) criteria comprise the first screening tool available to assess rational 
prescribing for children in UK hospitals and outpatient settings. Clinical validation and reliability 
studies are needed and planned by the authors in order to evaluate the usability and reliability of 
this tool, which it is hoped will be used to study the rational use of medicines in children in the UK. 
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